National Cancer Program

National Cancer Program
Name	National Cancer Program
Formed	1971
Jurisdiction	United States
Headquarters	Bethesda, Maryland
Parent agency	National Institutes of Health

National Cancer Program. It is a comprehensive, federally coordinated effort to reduce the burden of cancer in the United States. Established by the National Cancer Act of 1971, the program is spearheaded by the National Cancer Institute within the National Institutes of Health. Its mission encompasses the full spectrum of cancer research, from basic science to clinical application, and aims to accelerate progress in prevention, diagnosis, and treatment.

History and establishment

The program was formally created by the National Cancer Act of 1971, which was signed into law by President Richard Nixon. This landmark legislation was championed by figures like philanthropist Mary Lasker and Senator Jacob Javits, following years of advocacy from the American Cancer Society. The act significantly elevated the authority and resources of the National Cancer Institute, granting it a unique budgetary bypass directly to the President. Key early leaders included the first director, Dr. Frank J. Rauscher Jr., and influential advisors like Dr. Sidney Farber. The establishment of the program marked a major commitment by the U.S. Congress to a coordinated "war on cancer," modeled in part on large-scale scientific projects like the Apollo program.

Goals and objectives

The overarching goal is to substantially reduce the incidence, morbidity, and mortality of cancer. Primary objectives include advancing fundamental understanding of cancer biology through research in fields like genomics and immunology. It seeks to translate scientific discoveries into effective interventions, improving standards of care such as those set by the National Comprehensive Cancer Network. Another critical aim is to ensure the equitable dissemination of these advances across all populations, addressing disparities highlighted by studies from the SEER program. The program also focuses on supporting the next generation of scientists through training grants and fellowships.

Key initiatives and research areas

Major initiatives include The Cancer Genome Atlas, a collaborative project with the National Human Genome Research Institute to map genetic mutations in cancers. The Clinical Trials Cooperative Group Program facilitates large-scale studies across institutions like the Mayo Clinic and Memorial Sloan Kettering Cancer Center. Research areas span from developing targeted therapies, such as those pioneered by Dr. Brian Druker for chronic myelogenous leukemia, to advancing immunotherapy like CAR-T cell treatments. Prevention efforts include major studies like the SELECT trial and the promotion of HPV vaccination in collaboration with the Centers for Disease Control and Prevention.

Organizational structure and leadership

The National Cancer Institute serves as the lead agency, with its director, currently Dr. Monica M. Bertagnolli, providing overall scientific and administrative leadership. The program operates under the umbrella of the National Institutes of Health, headed by the NIH Director. Key advisory bodies include the National Cancer Advisory Board and the President's Cancer Panel, which provide recommendations to the Secretary of Health and Human Services. Research is conducted through a network of NCI-Designated Cancer Centers, such as the University of Texas MD Anderson Cancer Center, and divisions like the Division of Cancer Treatment and Diagnosis.

Funding and budget

Primary funding is allocated through the annual budget of the National Institutes of Health, as determined by the Congress and the White House Office of Management and Budget. The program also receives supplemental funding from specific legislative acts, such as the 21st Century Cures Act. A significant portion of the budget supports extramural research grants awarded to investigators at institutions like Harvard University and Stanford University. Additional funds are directed to large-scale infrastructure, including the Frederick National Laboratory for Cancer Research, and to contracts for drug development through initiatives like the NCI Experimental Therapeutics Program.

Impact and outcomes

The program has contributed to a sustained decline in overall cancer mortality rates in the U.S., as tracked by the American Cancer Society. It supported the basic research that led to breakthroughs like the development of tamoxifen and the discovery of the BRCA1 gene. Its clinical trials networks have established new standards of care for cancers such as Hodgkin lymphoma and testicular cancer. Initiatives like the Smokefree.gov campaign have contributed to reduced tobacco use. The program's data resources, including the SEER registry, are used globally by organizations like the World Health Organization.

Future directions and challenges

Future priorities include enhancing focus on cancers with poor prognoses, such as glioblastoma and pancreatic cancer, and expanding the use of artificial intelligence in research through collaborations with entities like the Department of Energy. A major challenge is addressing persistent disparities in cancer outcomes among racial, ethnic, and rural populations. The program is also working to streamline the clinical trial process and improve data sharing across systems like the Cancer Research Data Commons. Ongoing efforts aim to better understand the long-term effects of treatments and the biology of metastatic disease, ensuring continued progress against a complex set of diseases.

Category:National Institutes of Health Category:Cancer research Category:Government programs in the United States